Loading clinical trials...
Loading clinical trials...
Prospective Study of MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days
The Proseven trial is a prospective interventional study that will evaluate the toxicity and efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short overall treatment time (OTT) of 7 days. A simultaneous integrated boost (SIB) will be delivered to the intraprostatic dominant lesion (if present) in this study. Besides a potential biological impact of this innovative prostate SBRT treatment, the reduced OTT offers also benefits in terms of patient convenience. The primary endpoint is clinician reported grade 2 or more acute gastrointestinal (GI) and genitourinary (GU) toxicity, assessed using CTCAE v 5.0 and RTOG, measured up to 3 months after the first treatment fraction.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel
Brussels, Belgium
Start Date
August 10, 2021
Primary Completion Date
February 1, 2025
Completion Date
February 1, 2030
Last Updated
December 4, 2024
132
ESTIMATED participants
MR-guided RT
RADIATION
Lead Sponsor
Universitair Ziekenhuis Brussel
NCT05691465
NCT06842498
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04550494